Description

We are studying the interactions of buprenorphine-naloxone, a medication used to treat opiate dependence, and medications used in the treatment of HIV disease or Tuberculosis (TB).

Study Design

Individuals who agree to participate in this study will first be asked to come in for an eligibility screening visit to include a physical examination, interview, and blood and urine sampling. Those eligible to participate will be inducted onto buprenorphine. Once stabilized, participants will undergo a 24-hour blood and urine sampling procedure as an inpatient at San Francisco General Hospital (SFGH). Participants will then take standard clinical doses of the HIV or TB medication(s) being studied for 15 days. They will come to the research clinic at SFGH daily to have a check of how they are feeling while taking the medicine. After taking the medication for 15 days, participants will undergo a second 24-hour blood and urine sampling session. There will be a final medical evaluation, followed by a gradual taper off of buprenorphine or referral for continued treatment.

End Date

Principal Investigators

Participant Requirements

We are currently seeking participants who are addicted to heroin or prescription opioids (pain pills) and who are willing to take buprenorphine in addition to currently marketed HIV or TB medications. All participants must be free of HIV infection and willing to be tested for HIV. Female participants must not be pregnant or nursing. All participants must be age 18 or older.

Payment

Up to $750 for completion of all study procedures including medication administration, two 24-hour blood and urine sampling sessions, and a final medical examination.

Contact Info